Pseudotyped ΔG-GFP (G*ΔG-GFP) rVSV
ΔG-GFP is a replication-restricted, recombinant vesicular stomatitis virus (rVSV) that can be used to produce pseudotype viruses containing the envelope glycoproteins from a wide variety of heterologous viruses, including those that require BSL-3 or BSL-4 biocontainment; however, because the infectivity of rVSV-ΔG pseudotypes is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. These properties, together with the rapid replication kinetics of rVSV-ΔG pseudotypes, have proven useful in studies designed to identify cellular receptors for numerous viruses, and they also provide a robust platform to screen libraries for entry inhibitors and to evaluate the neutralizing antibody responses following vaccination [1].
When ordering this reagent, a vial of VSV-G pseudotyped ΔG-GFP (G*ΔG-GFP) will be sent which can directly be used to generate pseudotypes containing your envelope protein of choice by following the procedures described in [1]. Infection of cells with G*ΔG-GFP results in detectable GFP fluorescence within 4-6 hours of infection, and very bright GFP fluorescence by 12-18 hours post-infection. Infectivity can be quantified by fluorescence microscopy or flow cytometry. Because G*ΔG-GFP undergoes a single-round of infection, each GFP positive cell represents one infectious unit of virus. It is recommended that the user also order the plasmid pCAGGS-G, which is used to generate additional working stocks of G*ΔG-GFP.
It is the responsibility of the principal investigator to seek Institutional Biosafety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.
From the laboratory of Michael A. Whitt, Ph.D., University of Tennessee.
ΔG-GFP is a replication-restricted, recombinant vesicular stomatitis virus (rVSV) that can be used to produce pseudotype viruses containing the envelope glycoproteins from a wide variety of heterologous viruses, including those that require BSL-3 or BSL-4 biocontainment; however, because the infectivity of rVSV-ΔG pseudotypes is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. These properties, together with the rapid replication kinetics of rVSV-ΔG pseudotypes, have proven useful in studies designed to identify cellular receptors for numerous viruses, and they also provide a robust platform to screen libraries for entry inhibitors and to evaluate the neutralizing antibody responses following vaccination [1].
When ordering this reagent, a vial of VSV-G pseudotyped ΔG-GFP (G*ΔG-GFP) will be sent which can directly be used to generate pseudotypes containing your envelope protein of choice by following the procedures described in [1]. Infection of cells with G*ΔG-GFP results in detectable GFP fluorescence within 4-6 hours of infection, and very bright GFP fluorescence by 12-18 hours post-infection. Infectivity can be quantified by fluorescence microscopy or flow cytometry. Because G*ΔG-GFP undergoes a single-round of infection, each GFP positive cell represents one infectious unit of virus. It is recommended that the user also order the plasmid pCAGGS-G, which is used to generate additional working stocks of G*ΔG-GFP.
It is the responsibility of the principal investigator to seek Institutional Biosafety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.
From the laboratory of Michael A. Whitt, Ph.D., University of Tennessee.
| Catalog Number | Product | DataSheet | Size | AVAILABILITY | Price | Qty |
|---|
REQUIREMENTS
US customers - The USDA APHIS VS 16-6 or 16-6A permit must be obtained and a copy of the permit must be sent to Kerafast here, in advance of shipment. The Application Form VS 16-3 (Import controlled material import or transport organisms or vectors) must be submitted to USDA APHIS Veterinary Services to obtain the VS 16-6 or 16-6A permit.
Non-US customers - A BIS permit will be required in order to ship this product. Purchase restricted to End Users only. Please Contact Us for more information
| Product Type: | Virus |
| Biosafety Level: | BSL-2 |
| Vector Information: | G*ΔG-GFP was recovered using the VSV reverse genetics system as described in [1] from the plasmids pVSV-ΔG-GFP, pBS-N-ΦT, pBS-P-ΦT, pBS-G-ΦT and pBS-L-ΦT. Following recovery, a plaque isolate (plaques can be obtained on cells transiently expressing VSV-G) was amplified on BHK-21 cells transfected with pCAGGS-G. Secondary working stocks were generated by infecting BHK-21 cells transfected with pCAGGS-G at low multiplicity (MOI = 0.1) and titered on BHK-21 cells. |
| Virus: | VSV-G pseudotyped ΔG-GFP (G*ΔG-GFP) |
| Titer: | ≥ 6x10e8 IU/mL |
| Serotype: | Indiana/San Juan |
| Inoculation Conditions: | To generate pseudotypes with heterologous envelope glycoproteins, cells (BHK-21 or HEK-293) are first transfected with a plasmid expressing the glycoprotein of choice and ~24 hrs later infected with G*ΔG-GFP at a multiplicity (MOI) of ~3 to 5. To generate working stocks of G*ΔG-GFP, cells that have been transfected with pCAGGS-G are infected with G*ΔG-GFP at low multiplicity (MOI = 0.1) and culture supernatants harvested ~18-24 hrs post-infection. |
| Comments: | For suggested protocol, see: Whitt, MA, J. Virol. Methods, 2010. 169(2): p. 365-74. |
| Storage: | Store at -80C. Multiple freeze/thaw cycles not recommended. |
| Shipped: | Frozen on Dry ice |
Virus stocks are stable if stored frozen at -70 to -80C. Stocks should be frozen and thawed no more than 3 times without significant loss of infectivity. To produce additional working stocks of G*deltaG-GFP, see Inoculations Conditions above.
- Whitt, M.A., Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods, 2010. 169(2): p. 365-74.
- Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ,Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD,He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, FoungSK, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM,Aman MJ. Antibody Treatment of Ebola and Sudan Virus Infection via a UniquelyExposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Rep. 2016 May17;15(7):1514-26. View Article
- Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017 May 18;169(5):891-904.e15. View Article
- Salata C, Baritussio A, Munegato D, Calistri A, Ha HR, Bigler L, Fabris F,Parolin C, Palù G, Mirazimi A. Amiodarone and metabolite MDEA inhibit Ebola virusinfection by interfering with the viral entry process. Pathog Dis. 2015Jul;73(5). pii: ftv032. View Article
- Samuel RM, Majd H, Richter MN, Ghazizadeh Z, Zekavat SM, Navickas A, Ramirez JT, Asgharian H, Simoneau CR, Bonser LR, Koh KD, Garcia-Knight M, Tassetto M, Sunshine S, Farahvashi S, Kalantari A, Liu W, Andino R, Zhao H, Natarajan P, Erle DJ, Ott M, Goodarzi H, Fattahi F. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. Cell Stem Cell. 2020 Dec 3;27(6):876-889.e12. View Article
If you publish research with this product, please let us know so we can cite your paper.
